Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration

Annals of the New York Academy of Sciences

Volumn 1035, Issue , 2004, Pages 1-20

  Turner, Anthony J ^a   Fisk, Lilia ^a   Nalivaeva, Natalia N ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid peptide; Amyloid degrading enzymes; Endothelin converting enzyme; Insulin degrading enzyme; Neprilysin; Neurodegeneration; Plasmin

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ATRIAL NATRIURETIC FACTOR; BATIMASTAT; BETA SECRETASE; BOMBESIN; CARBACHOL; CHEMOTACTIC PEPTIDE; CORTICOTROPIN; ENDOTHELIN CONVERTING ENZYME; GAMMA SECRETASE; GELATINASE B; GUANOSINE TRIPHOSPHATASE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MEMBRANE PROTEIN; MUSCARINE; NICASTRIN; OPIATE PEPTIDE; PLASMIN; PRESENILIN 1; PRESENILIN 2; PROTEINASE ACTIVATED RECEPTOR 4; SERINE PROTEINASE; SUBSTANCE P; TACHYKININ; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; GENE TARGETING; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; SENILE PLAQUE;

EID: 14944344493     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1332.001     Document Type: Conference Paper

References (128)

1. LICHTENTHALER, S.F. & C. HAASS. 2004. Amyloid at the cutting edge: activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J. Clin. Invest. 113: 1384-1387.
2. HARDY, J. 2004. Toward Alzheimer therapies based on genetic knowledge. Annu. Rev. Med. 55: 15-25.
3. HARDY, J. & D. SELKOE. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
4. KOUDINOV, A.R. & T.T. BEREZOV. 2004. Alzheimer's amyloid-β (Aβ) is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol. Exp. (Wars) 64: 71-79.
5. 2+ channel activity by β-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1β. J. Biol. Chem. 275: 4713-4718.
6. MOLNAR, Z. et al. 2004. Enhanced G-protein activation by a mixture of Aβ(25-35), Aβ(1-40/42) and zinc. J. Neurochem. 89: 1215-1223.
7. LAMMICH, S. et al. 1999. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA 96: 3922-3927.
8. PARVATHY, S. et al. 1998. Alzheimer's amyloid precursor protein α-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase. Biochemistry 37: 1680-1685.
9. BUXBAUM, J.D. et al. 1992. Cholinergic agonists and interleukin 1 regulated processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89: 10075-10078.
10. ALLINSON, T.M. et al. 2003. ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci. Res. 74: 342-352.
11. CANET-AVILES, R.M. et al. 2002. Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(α), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. Brain Res. Mol. Brain Res. 102: 62-72.
12. ZHU, G. et al. 2001. Protein kinase C ε suppresses Aβ production and promotes activation of α-secretase. Biochem. Biophys. Res. Commun. 285: 997-1006.
13. POSTINA, R. et al. 2004. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113: 1456-1464.
14. MATTSON, M. 2004. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
15. VASSAR, R., & M. CITRON. 2000. Aβ-generating enzymes: recent advances in β- and γ-secretase search. Neuron 27: 419-422.
16. VASSAR, R. 2004. BACE1: the β-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 23: 105-114.
17. LUO, Y. et al. 2001. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 4: 231-232.
18. NAWROT, B. 2004. Targeting BACE with small inhibitory nucleic acids-a future for Alzheimer's disease therapy? Acta Biochim. Pol. 51: 431-444.
19. MARTOGLIO, B. & T.E. GOLDE. 2003. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. Hum. Mol. Genet. 12: R201-R206.
20. DE STROOPER, B. 2003. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38: 9-12.
21. EL-AGNAF, O.M. et al. 2000. Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273: 1003-1007.
22. LICHTENTHALER, S.F. et al. 1999. Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 96: 3053-3058.
23. SHEN, J. et al. 1997. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89: 629-639.
24. SHIROTANI, K. et al. 2004. Identification of distinct γ-secretase complexes with different APH-1 variants. J. Biol. Chem. Jul 30 [Epub ahead of print].
25. HELDIN, C.H & J. ERICSSON. 2001. Signal transduction. RIPping tyrosine kinase receptors apart. Science 294: 2111-2113.
26. MATTSON, M.P. et al. 2001. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 6: 69-81.
27. LEE, H.-G. et al. 2004, Challenging the amyloid cascade hypothesis: senile plaques and amyloid-β as protective adaptations to Alzheimer disease. Ann. N.Y. Acad. Sci. 1019: 1-4.
28. MEHTA, P.D. et al. 2001. Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304: 102-106.
29. WELLER, R.O. et al. 2002. Cerebrovascular disease is a major factor in the failure of elimination of Aβ from the aging human brain. Ann. N. Y. Acad. SCi. 977: 162-168.
30. CARSON, J.A. & A.J. TURNER. 2002. β-Amyloid catabolism: role for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81: 1-8.
31. LEISSRING, M.A. et al. 2003. Kinetics of amyloid β-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278: 37314-37320.
32. TURNER, A.J. & K. TANZAWA. 1997. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 11: 355-364.
33. MATSAS, R., A.J. KENNY & A.J. TURNER. 1986. An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system. Neuroscience 18: 991-1012.
34. TURNER, A.J. 1990. Neuropeptide signalling and cell-surface peptidases. Adv. Second. Messenger Phosphoprotein Res. 24: 467-471.
35. SALES, N. et al. 1991. Neutral endopeptidase 24.11 in rat peripheral tissues: comparative localization by "ex vivo" and "in vitro" autoradiography. Regul. Pept. 33: 209-222.
36. LETARTE, M. et al. 1988. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. Exp. Med. 168: 1247-1253.
37. LEBIEN, T.W. & R.T. MCCORMACK. 1989. The common acute lymphoblastic leukemia antigen (CD10)-emancipation from a functional enigma. Blood 73: 625-635
38. SHIPP, M.A. et al. 1991. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA 88: 10662-10666.
39. DUVAUX-MIRET, O. et al. 1992. Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoreactive neuropeptides. Proc. Natl. Acad. Sci. USA 89: 778-781.
40. HARRISON, N. K. et al. 1995. Effects of neuropeptides on human lung fibroblast proliferation and chemotaxis. Lung Cell. Mol. Physiol. 12: L278-L283.
41. ROQUES, B.P. et al. 1993. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45: 87-146.
42. ERDOS, E.G. & R.A. SKIDGEL. 1989. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3: 145-151.
43. CONNELLY, J.C. et al. 1985. Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide. Proc. Natl. Acad. Sci. USA 82: 8737-8741.
44. MAPP, P.I. et al. 1992. Localization of the enzyme neutral endopeptidase to the human synovium. J. Rheumatol. 19: 1838-1844.
45. PIERART, M.E. et al. 1988. Effect of human endopeptidase 24.11 ("enkephalinase") on IL-1-induced thymocyte proliferation activity. J. Immunol. 140: 3808-3811.
46. IWATA, N. et al. 2000. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 6: 143-150.
47. SAITO, T. et al. 2003. Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-β peptide metabolism. Sci. Aging Knowledge Environ. 3: PE1.
48. SHIROTANI, K. et al. 2001. Neprilysin degrades both amyloid β peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276: 21895-21901.
49. KANEMITSU, H. et al. 2003. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form, but also the pathological oligomeric form. Neurosci. Lett. 350: 113-116.
50. YASOJIMA, K. et al. 2001. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297: 97-100.
51. BARNES, K., A.J. TURNER & A.J. KENNY. 1992. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry. J. Neurochem. 58: 2088-2096.
52. IWATA, N. et al. 2002. Region-specific reduction of Aβ-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70: 493-500.
53. NALIVAEVA, N.N. et al. 2004. Effects of prenatal hypoxia on expression of amyloid precursor protein and metallopeptidases in the rat brain. Lett. Peptide Sci. 10: 455-462.
54. NALIVAEVA, N.N. et al. 2004. Effect of hypoxia/ischaemia and hypoxic preconditioning/reperfusion on expression of some amyloid degrading enzymes. Ann. N.Y. Acad. Sci. This volume.
55. APELT, J., K. ACH & R. SCHLIEBS. 2003. Ageing-related downregulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques. Neurosci. Lett. 339: 183-186.
56. SAKAI, A. et al. 2004. Association of the neprilysin gene with susceptibility to late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 17: 164-169.
57. LILIUS, L. et al. 2003. No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neurosci. Lett. 337: 111-113.
58. ODA, M. et al. 2002. Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci. Lett. 320: 105-107.
59. FACCHINETTI, P. et al. 2003. Ontogeny, regional and cellular distribution of the novel metalloprotease neprilysin 2 in the rat: a comparison with neprilysin and endothelin-converting enzyme-1. Neuroscience 118: 627-639.
60. LEISSRING. M.A. et al. 2003. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40: 1087-1093.
61. DUCKWORTH, W.C., R.G. BENNETT & F.G. HAMEL. 1998. Insulin degradation: progress and potential. Endocr. Rev. 19: 608-624.
62. SETA, K.A. & R.A. ROTH. 1997. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem. Biophys. Res. Commun. 231: 167-171.
63. VEKRELLIS, K. et al. 2000. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20: 1657-1665.
64. QIU, W.Q. et al. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273: 32730-32738.
65. LEISSRING, M.A. et al. 2004. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem. J. [Epub ahead of print.]
66. KUROCHKIN, I.V. & S. GOTO. 1994. Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345: 33-37.
67. KUROCHKIN, I.V. 2001. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26: 421-425.
68. PEREZ, A. et al. 2000. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2: 247-255.
69. LEISSRING, M.A. et al. 2003. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40: 1087-1093.
70. 125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 80: 1033-1040.
71. BIGL, M. et al. 2003. Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J. Neural. Transm. 110: 77-94.
72. LING, X. et al. 2002. Amyloid β antagonizes insulin promoted secretion of the amyloid β protein precursor. J. Alzheimers Dis. 4: 369-374.
73. XIE, L. et al. 2002. Alzheimer's β-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22: RC221.
74. FARRIS, W. et al. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100: 4162-4167.
75. FARRIS, W. et al. 2004. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am. J. Pathol. 164: 1425-1434.
76. HO, L. et al. 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18: 902-904.
77. SCHMITZ, A. et al. 2004. Endoplasmic reticulum-localized amyloid β-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic 5: 89-101.
78. GROSSMAN, H. 2003. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr. 8: 815-823.
79. PRINCE, J.A. et al. 2003. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum. Mutat. 22: 363-371.
80. BOUSSAHA, M. et al. 2002. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci. Lett. 329: 121-123.
81. BLOMQVIST, M.E. et al. 2004. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics 5: 115-119.
82. BARNES, K. & A.J. TURNER. 1999. The endothelin converting enzyme is located on α-actin filaments in smooth muscle cells. Cardiovasc. Res. 42: 814-822.
83. BARNES, K & A.J. TURNER. 1997. The endothelin system and endothelin-converting enzyme in the brain: molecular and cellular studies. Neurochem. Res. 22: 1033-1040.
84. VALDENAIRE, O., E. ROHRBACHER & M.G. MATTEL 1995. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J. Biol. Chem. 270: 29794-2978.
85. SCHWEIZER, A. et al. 1997. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem. J. 328: 871-877.
86. HOANG, M.V. & A.J. TURNER. 1997. Novel activity for endothelin-converting enzyme: hydrolysis of bradykinin. Biochem. J. 327: 23-26.
87. EMOTO, N. & M. YANAGISAWA. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phorphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270: 15262-15268.
88. ECKMAN, E.A., D.K. REED & C.B. ECKMAN. 2001. Degradation of the Alzheimer's amyloid β peptide by endothelin-converting enzyme. J. Biol. Chem. 276: 24540-24548.
89. ECKMAN, E.A. et al. 2003. Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278: 2081-2084.
90. WERB, Z. 1997. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442.
91. TSIRKA, S.E., A.D. ROGOVE & S. STRICKLAND. 1996. Neuronal cell death and tPA. Nature 384: 123-124.
92. NAKAGAMI, Y. et al. 2000. Laminin degradation by plasmin regulates long-term potentiation. J. Neurosci. 20: 2003-2010.
93. MADANI, R., S. NEF & J.D. VASSALLI. 2003. Emotions are building up in the field of extracellular proteolysis. Trends Mol. Med. 9: 183-185.
94. PFEFFERKORN, T. et al. 2000. Plasminogen activation in experimental permanent focal cerebral ischemia. Brain Res. 882: 19-25.
95. LEDESMA, M.D. et al. 2000. Brain plasmin enhances APP α-cleavage and Aβ degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1: 530-535.
96. LEDESMA, M.D. et al. 2003. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep. 4: 1190-1196.
97. VAN NOSTRAND, W.E. & M. PORTER. 1999. Plasmin cleavage of the amyloid β-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38: 11570-11576.
98. TUCKER, H.M. et al. 2000. The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci. 20: 3937-3946.
99. TUCKER, H.M. et al. 2000. Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J. Neurochem. 75: 2172-2177.
100. LEDESMA, M.D. et al. 2003. Proteomic characterisation of neuronal sphingolipid-cholesterol microdomains: role in plasminogen activation. Brain Res. 987: 107-116.
101. EHEHALT, R. et al. 2003. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160: 113-123.
102. CORDY, J.M. et al. 2003. Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 100: 11735-11740.
103. KINGSTON, I.B., M.J.M. CASTRO & S.A. ANDERSON. 1995. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues. Nat. Med. 1: 138-142.
104. ERTEKIN-TANER, N. et al. 2000. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290: 2303-2304.
105. TUCKER, H.M., M. KIHIKO-EHMANN & S. ESTUS. 2002. Urokinase-type plasminogen activator inhibits amyloid-β neurotoxicity and fibrillogenesis via plasminogen. J. Neurosci. Res. 70: 249-255.
106. HU, J. et al. 2001. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 276: 47863-47868.
107. BACKSTROM, J.R. et al. 1996. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40). J. Neurosci. 16: 7910-7919.
108. RANGAN, S.K. et al. 2003. Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 42: 14328-14334.
109. LIU, R. et al. 2004. Proteolytic antibody light chains alter β-amyloid aggregation and prevent cytotoxicity. Biochemistry 43: 9999-10007.
110. PERRY, T.A. & N.H. GREIG. 2004. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 5: 565-571.
111. GOLOMB, J. et al. 1993. Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch. Neurol. 50: 967-973.
112. MONTINE, T.J. et al. 2002. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33: 620-626.
113. 2+ and mitochondria as substrates for deficits in synaptic plasticity in normal brain aging. J. Cell. Mol. Med. 8: 181-190.
114. CUTLER, R.G. et al. 2004. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101: 2070-2075.
115. WELLER, R.O. et al. 2000. Cerebral amyloid angiopathy: accumulation of Aβ in interstitial fluid drainage pathways in Alzheimer's disease. Ann. N.Y. Acad. Sci. 903: 110-117.
116. BUTTERFIELD, D.A. et al. 2002. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. 7: 548-554.
117. LAUDERBACK, C.M. et al. 2001. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J. Neurochem. 78: 413-416.
118. SAYRE, L.M. et al. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68: 2092-2097.
119. WANG, D.S. et al. 2003. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 310: 236-241.
120. REISER, M. et al. 1987. Proteolytic degradation of insulin and glucagon in rat brain during ontogenesis. Acta Histochem. 82: 35-39.
121. ZULIANI, G. et al. 2004. Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J. Gerontol. A. Biol. Sci. Med. Sci. 59: 293-297.
122. ROHER, A.E. et al. 2002. Increased A β peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 37: 11080-11090.
123. NYAKAS, C., B. BUWALDA & P.O. LUITEN. 1996. Hypoxia and brain development. Prog. Neurobiol. 49: 1-51.
124. DOLINAK, D., C. SMITH & D.I. GRAHAM. 2000. Global hypoxia per se is an unusual cause of axonal injury. Acta Neuropathol. (Berl.) 100: 553-560.
125. YEPES, M. & D.A. LAWRENCE. 2004. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc. Med. 14: 173-180.
126. IWATA, N. et al. 2004. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-β peptide in mouse brain. J. Neurosci. 24: 991-998.
127. MARR, R.A. et al. 2003. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23: 1992-1996.
128. LEVITES, Y. et al. 2003. Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17: 952-954.